Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Aethlon Medical To Present At 4th Annual Sachs Cancer Bio Partnering & Investment Forum On February 24, 2016

AEMD

SAN DIEGO, Feb. 18, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the 4th Annual Sachs Cancer Bio Partnering & Investment Forum at the New York Academy of Sciences in New York, NY at 2:20 p.m. ET on Wednesday, February 24, 2016. 

Aethlon Hemopurifier. (PRNewsFoto/Aethlon Medical, Inc.)

About Aethlon Medical, Inc.

Aethlon Medical creates affinity biofiltration devices to treat life-threatening diseases. The Aethlon Hemopurifier® is a leading broad-spectrum treatment countermeasure against infectious viral pathogens.  The device, which has been successfully administered to individuals infected with HIV, Hepatitis C (HCV) and Ebola virus, is currently the subject of FDA approved clinical studies. Aethlon is also studying the potential use of the Hemopurifier® to address exosomes secreted by tumors to promote the spread of metastasis and suppress the immune system of cancer patients.  The Company provides government contracting services to the Defense Advanced Research Projects Agency (DARPA) related to the development of a biofiltration device to treat sepsis and maintains majority ownership of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor Chronic Traumatic Encephalopathy (CTE) and other neurological disorders.  Additional information can be found online at www.AethlonMedical.com or you can connect with us on Twitter, LinkedIn, Facebook and Google+.

About the 4th Annual Sachs Cancer Bio Partnering & Investment Forum

The 4th Annual Sachs Cancer Bio Partnering & Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharmaceutical, and biotech to facilitate partnering and funding/investment. The conference will attract approximately 250 delegates and 30 company presentations by listed and private biotechnology companies seeking licensing and investment opportunities. The event provides a platform for one-on-one meetings and dedicated meeting facilities to make the event more productive. For more information, please visit: http://www.sachsforum.com/.

Contacts:

Mike Smargiassi/Brad Edwards
Brainerd Communicators, Inc
212-986-6667
smarg@braincomm.com

Photo - http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aethlon-medical-to-present-at-4th-annual-sachs-cancer-bio-partnering--investment-forum-on-february-24-2016-300221799.html

SOURCE Aethlon Medical, Inc.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today